Oxford BioMedica PLC
LSE:OXB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
167.2
445
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Oxford BioMedica PLC
Oxford BioMedica PLC
Other Current Liabilities
Oxford BioMedica PLC
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Other Current Liabilities
£27.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
41%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Other Current Liabilities
$112k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Other Current Liabilities
£29.1m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Other Current Liabilities
$11.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other Current Liabilities
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Other Current Liabilities
£8.5m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-2%
|
|
Oxford BioMedica PLC
Glance View
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
See Also
What is Oxford BioMedica PLC's Other Current Liabilities?
Other Current Liabilities
27.4m
GBP
Based on the financial report for Jun 30, 2024, Oxford BioMedica PLC's Other Current Liabilities amounts to 27.4m GBP.
What is Oxford BioMedica PLC's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
41%
Over the last year, the Other Current Liabilities growth was 16%. The average annual Other Current Liabilities growth rates for Oxford BioMedica PLC have been 6% over the past three years , 6% over the past five years , and 41% over the past ten years .
You don't have any saved screeners yet
